Register Login

EIKON THERAPEUTICS, INC. (EIKN)

(90% Positive) EIKON THERAPEUTICS, INC. (EIKN) Announces Enrollment Update for optimization Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Aug. 13, 2026, 8:08 p.m.

    📋 EIKON THERAPEUTICS, INC. (EIKN) - Clinical Trial Update

    Filing Date: 2026-08-13

    Accepted: 2026-08-13 16:06:11

    Event Type: Clinical Trial Update

    Event Details:

    EIKON THERAPEUTICS, INC. (EIKN) Announces Clinical Trial Update EIKON THERAPEUTICS, INC. (EIKN) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: optimization, patients
    • Diseases/Conditions: first-line advanced melanoma •Appointed Ma, advanced
    • Clinical Stage: Phase 2, Phase 2 trial
    • Collaboration: NSCLC
      • targeting the DNA damage response of cancer cells. EIK1004

    🔬 Clinical Development Pipeline (EIKON THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    EIK1005 Other Phase PHASE1 Advanced Solid Tumors ClinicalTrials.gov
    EIK1001 Other Phase PHASE2 NSCLC ClinicalTrials.gov
    Paclitaxel Other Phase PHASE2 NSCLC ClinicalTrials.gov
    EIK1001 Other Phase PHASE2 Advanced Melanoma ClinicalTrials.gov
    EIK1005 DRUG Phase PHASE1 Advanced Solid Tumors ClinicalTrials.gov
    Carboplatin Other Phase PHASE2 NSCLC ClinicalTrials.gov
    Pemetrexed Other Phase PHASE2 NSCLC ClinicalTrials.gov
    Pembrolizumab Other Phase PHASE2 NSCLC ClinicalTrials.gov
    Pembrolizumab (KEYTRUDA® ) Other Phase PHASE2 Advanced Melanoma ClinicalTrials.gov
    Atezolizumab Other Phase PHASE1 Tumor, Solid ClinicalTrials.gov
    BDB001 (EIK1001) Other Phase PHASE1 Tumor, Solid ClinicalTrials.gov
    Association atezolizumab + BDB001 + RT Other Phase PHASE2 Solid Tumor, Adult ClinicalTrials.gov
    Association atezolizumab + BDB001+ RT Other Phase PHASE2 Solid Tumor, Adult ClinicalTrials.gov
    BDB018 Other Phase PHASE1 Tumor, Solid ClinicalTrials.gov
    BDB001 Other Phase PHASE2 Tumor, Solid ClinicalTrials.gov
    EIK1004-001 (IMP1707-001) DRUG Phase PHASE1 Advanced Solid Tumors ClinicalTrials.gov
    IMP1734 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: EIKON THERAPEUTICS, INC.
    • Ticker Symbol: EIKN

Search

News categories